This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Gregory Moore, Ph.D.
Director, Protein Engineering at Xencor


Dr. Moore is a Director in the Protein Engineering department at Xencor, Inc. Since joining Xencor in 2004, Dr. Moore has made many contributions to the company’s technology platform, including antibodies with increased affinity for the inhibitory receptor CD32b, bispecifics with heterodimeric Fc regions, and antibodies with enhanced recruitment of complement. Currently, his work focuses on the design of antibody-based bispecifics and antibody Fc engineering, humanization, and affinity maturation. Prior to Xencor, Dr. Moore was a graduate student at Penn State University, where he developed computational models and optimization methods for protein engineering and directed evolution protocols. Dr. Moore holds a Ph.D. and B.S. in Chemical Engineering from Penn State University.

Agenda Sessions

  • Tumor-targeted CD28 Costimulatory Bispecific Antibodies Enhance T Cell Activation in Solid Tumors


Speakers at this event